Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
Nuclera @nuclera has closed a Series C round of funding, and was highlighted on the NASDAQ in New York. They are one of the many companies providing tools for #SynBio #SyntheticBiology work, and their eProtein platform has already been in customers' hands for a while. https://t.co/EevrgDjrK0
Exciting news! 🎉 @nuclera has secured $75M in Series C financing to accelerate the commercialization of their eProtein Discovery™ system. 🔗Read the full release here: https://t.co/xuCl77NEej #Nuclera #SeriesC #biotech #proteinexpression #drugdiscovery https://t.co/ygb6APKWYz
Nuclera Closes $75 Million USD Financing https://t.co/03ZGF4vCeF https://t.co/gpC5vrQb3u
Northern Ireland's Cirdan has secured £7.5 million to enhance diagnostic accuracy and healthcare performance through its advanced technology. Cardiff-based Antiverse raised €4.2 million to advance its generative AI antibody design platform, with funding led by Kadmos Capital and i&i Biotech Fund I. Additionally, Antiverse announced a £3.5 million ($4.6 million) investment to further develop its antibody design technology. Nuclera has raised $75 million in a Series C funding round to accelerate the commercialization of its eProtein Discovery™ system, which is used in protein manufacturing technology and is already in customers' hands. The funding was highlighted on the NASDAQ in New York.
